Novavax reported $-302882000 in EBITDA for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Adamas Pharmaceuticals ADMS:US -5502000 3.51M
Adma Biologics ADMA:US $ -13.02M 1.24M
Astrazeneca AZN:US $ 2784M 588M
AstraZeneca AZN:LN 2784M 588M
Genocea Biosciences GNCA:US $ -11.32M 2.86M
Geron GERN:US $ -25.62M 3.22M
GlaxoSmithKline GSK:LN 3660M 1034M
Kindred Biosciences KIN:US $ -7.33M 0.63M
Mannkind MNKD:US $ -7.23M 0.79M
Minerva Neurosciences NERV:US $ -7.52M 1.44M
Moderna Inc MRNA:US 3.63B 497M
Novartis NVS:US $ 4837M 65M
Novavax NVAX:US $ -302.88M 40.54M
Pain Therapeutics PTIE:US $ -9.54M 4.41M
Peregrine Pharmaceuticals PPHM:US $ 7.94M 3.85M
Pfizer PFE:US $ 10235M 2245M
Sarepta Therapeutics SRPT:US $ -23.96M 135.16M